STRO Earnings — Sutro Biopharma, Inc. Post-ER Performance | BigEarnings
STRO — Sutro Biopharma, Inc.
XNAS · Healthcare · Biotechnology
Price$30.12
Market Cap$492.0M
P/E—
52W Range$6.74 – $43.85
Next Earnings2026-08-06
About Sutro Biopharma, Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
